• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CZD
Click for more information
3.13% 9.3¢

CALZADA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CZD Change of Company Name28/11/14
CZD Calzada to Divest MetabolicPRICE SENSITIVE21/11/14
CZD Change of Director's Interest Notice20/11/14
CZD Change of Director's Interest Notice20/11/14
CZD Change of Director's Interest Notice20/11/14
CZD Change of Director's Interest Notice20/11/14
CZD Appendix 3B18/11/14
CZD Results of Meeting17/11/14
CZD Chairmans Address17/11/14
CZD Appointment of Chief Executive OfficerPRICE SENSITIVE13/11/14
CZD FDA Pre-Submission Meeting31/10/14
CZD US Regulatory UpdatePRICE SENSITIVE23/10/14
CZD Annual Report16/10/14
CZD Notice of Annual General Meeting/Proxy Form16/10/14
CZD International Society for Burn Injuries Presentation14/10/14
CZD TGA Notice29/09/14
CZD Change of Director's Interest Notice17/09/14
CZD Director Resignation10/09/14
CZD Full Year Statutory AccountsPRICE SENSITIVE25/08/14
CZD PolyNovo Market Update12/08/14
CZD Financial Result GuidancePRICE SENSITIVE06/08/14
CZD Calzada Update on Metabolic PharmaceuticalsPRICE SENSITIVE31/07/14
CZD PolyNovo Receives CE Mark Approval for NovoPorePRICE SENSITIVE21/07/14
CZD Significant Organisational Structure InitiativesPRICE SENSITIVE15/07/14
CZD Change of Director's Interest Notice04/07/14
CZD Appendix 3B04/07/14
CZD Results of Meeting01/07/14
CZDBurn Clinical Trial Update05/06/14
CZDNotice of Extraordinary General Meeting/Proxy Form29/05/14
CZDChange of Director's Interest Notice21/05/14
CZDInitial Director's Interest Notice15/05/14
CZDInitial Director's Interest Notice15/05/14
CZDBoard Appointments14/05/14
CZDAppendix 3B04/04/14
CZDAppendix 3B25/03/14
CZDAppointment of Mr David Williams as Chairman13/03/14
CZDResponse to ASX QueryPRICE SENSITIVE04/03/14
CZDInitial Director's Interest Notice03/03/14
CZDMr David Williams to join the Calzada Board28/02/14
CZDHalf Yearly Report and AccountsPRICE SENSITIVE24/02/14
CZDHalf Year Financial Result GuidancePRICE SENSITIVE13/02/14
CZDRAH Surgeons Receive Approval to use BTMPRICE SENSITIVE04/02/14
CZDMetabolic Licenses AOD9604PRICE SENSITIVE28/01/14
CZDNovoSorb BTM Burn TrialPRICE SENSITIVE23/12/13
CZDAppendix 3B04/12/13
CZDAppendix 3B26/11/13
CZDFinal Director's Interest Notice19/11/13
CZDInitial Director's Interest Notice19/11/13
CZDChanges to the Calzada Board15/11/13
CZDResults of Meeting15/11/13
CZDChairmans Address15/11/13
CZDAGM Presentation15/11/13
CZDAppendix 3B14/11/13
CZDAppendix 3B07/11/13
CZDAppendix 3B28/10/13
CZDAppendix 3B17/10/13
CZDAnnual Report to shareholders15/10/13
CZDNotice of Annual General Meeting/Proxy Form15/10/13
CZDSuccessful Clinical Trial Outcomes for NovoSorb BTMPRICE SENSITIVE10/10/13
CZDAusbiotech Presentation19/09/13
CZD510(k) Regulatory Submission For NovoSorb Wound Dressing18/09/13
CZDResponse to ASX Price and Volume QueryPRICE SENSITIVE11/09/13
CZDFull Year Statutory AccountsPRICE SENSITIVE28/08/13
CZDChange in substantial holding20/08/13
CZDFinancial Result GuidancePRICE SENSITIVE16/08/13
CZDAppendix 3B07/08/13
CZDResponse to Media SpeculationPRICE SENSITIVE29/07/13
CZDTrading halt and requestPRICE SENSITIVE29/07/13
CZDFinal Patient Treated in NovoSorb BTM Clinical TrialPRICE SENSITIVE26/07/13
CZDChange of Director's Interest Notice26/07/13
CZDChange of Director's Interest Notice26/07/13
CZDAppendix 3B25/07/13
CZDClosing of Share Purchase Plan23/07/13
CZDNovoSorb Hernia Repair Feasibility AgreementPRICE SENSITIVE17/07/13
CZDPolyNovo Partners in the Field of Aesthetic Facial SurgeryPRICE SENSITIVE09/07/13
CZDShare Purchase PlanPRICE SENSITIVE19/06/13
CZDAppendix 3B and Section 708A Notice14/06/13
CZDShareholder Update12/06/13
CZDPlacement and Share Purchase PlanPRICE SENSITIVE12/06/13
CZDTrading HaltPRICE SENSITIVE07/06/13
CZDInvestor Overview06/06/13
CZDAmerican Burns Association Presentations26/04/13
CZDAOD9604 Important ClarificationsPRICE SENSITIVE26/04/13
CZDPositive Results from NovoSorb Human Clinical TrialPRICE SENSITIVE17/04/13
CZDAppendix 3B12/04/13
CZDTopical Negative Pressure Human Trial CompletedPRICE SENSITIVE28/03/13
CZDHalf Yearly Report and AccountsPRICE SENSITIVE25/02/13
CZDUS BARDA Contract Application and BTM Trial UpdatePRICE SENSITIVE18/02/13
CZDHalf Year Financial Result GuidancePRICE SENSITIVE15/02/13
CZDAOD9604 Positive in Osteoarthritis Animal ModelPRICE SENSITIVE05/02/13
CZDPolyNovo Concludes Recruitment for VAC TrialPRICE SENSITIVE04/02/13
CZDR and D Tax Refund ReceivedPRICE SENSITIVE30/01/13
CZDChange of Director's Interest Notice02/01/13
CZDChange in substantial holding03/12/12
CZDChange of Director's Interest Notice21/11/12
CZDChange of Director's Interest Notice21/11/12
CZDChange of Directors Interest Notice21/11/12
CZDAppendix 3B21/11/12
CZDFinal Director's Interest Notice15/11/12
CZDResults of Meeting14/11/12
CZD Change of Company Name
28/11/14
CZD Calzada to Divest Metabolic
21/11/14PRICE SENSITIVE
CZD Change of Director's Interest Notice
20/11/14
CZD Change of Director's Interest Notice
20/11/14
CZD Change of Director's Interest Notice
20/11/14
CZD Change of Director's Interest Notice
20/11/14
CZD Appendix 3B
18/11/14
CZD Results of Meeting
17/11/14
CZD Chairmans Address
17/11/14
CZD Appointment of Chief Executive Officer
13/11/14PRICE SENSITIVE
CZD FDA Pre-Submission Meeting
31/10/14
CZD US Regulatory Update
23/10/14PRICE SENSITIVE
CZD Annual Report
16/10/14
CZD Notice of Annual General Meeting/Proxy Form
16/10/14
CZD International Society for Burn Injuries Presentation
14/10/14
CZD TGA Notice
29/09/14
CZD Change of Director's Interest Notice
17/09/14
CZD Director Resignation
10/09/14
CZD Full Year Statutory Accounts
25/08/14PRICE SENSITIVE
CZD PolyNovo Market Update
12/08/14
CZD Financial Result Guidance
06/08/14PRICE SENSITIVE
CZD Calzada Update on Metabolic Pharmaceuticals
31/07/14PRICE SENSITIVE
CZD PolyNovo Receives CE Mark Approval for NovoPore
21/07/14PRICE SENSITIVE
CZD Significant Organisational Structure Initiatives
15/07/14PRICE SENSITIVE
CZD Change of Director's Interest Notice
04/07/14
CZD Appendix 3B
04/07/14
CZD Results of Meeting
01/07/14
CZDBurn Clinical Trial Update
05/06/14
CZDNotice of Extraordinary General Meeting/Proxy Form
29/05/14
CZDChange of Director's Interest Notice
21/05/14
CZDInitial Director's Interest Notice
15/05/14
CZDInitial Director's Interest Notice
15/05/14
CZDBoard Appointments
14/05/14
CZDAppendix 3B
04/04/14
CZDAppendix 3B
25/03/14
CZDAppointment of Mr David Williams as Chairman
13/03/14
CZDResponse to ASX Query
04/03/14PRICE SENSITIVE
CZDInitial Director's Interest Notice
03/03/14
CZDMr David Williams to join the Calzada Board
28/02/14
CZDHalf Yearly Report and Accounts
24/02/14PRICE SENSITIVE
CZDHalf Year Financial Result Guidance
13/02/14PRICE SENSITIVE
CZDRAH Surgeons Receive Approval to use BTM
04/02/14PRICE SENSITIVE
CZDMetabolic Licenses AOD9604
28/01/14PRICE SENSITIVE
CZDNovoSorb BTM Burn Trial
23/12/13PRICE SENSITIVE
CZDAppendix 3B
04/12/13
CZDAppendix 3B
26/11/13
CZDFinal Director's Interest Notice
19/11/13
CZDInitial Director's Interest Notice
19/11/13
CZDChanges to the Calzada Board
15/11/13
CZDResults of Meeting
15/11/13
CZDChairmans Address
15/11/13
CZDAGM Presentation
15/11/13
CZDAppendix 3B
14/11/13
CZDAppendix 3B
07/11/13
CZDAppendix 3B
28/10/13
CZDAppendix 3B
17/10/13
CZDAnnual Report to shareholders
15/10/13
CZDNotice of Annual General Meeting/Proxy Form
15/10/13
CZDSuccessful Clinical Trial Outcomes for NovoSorb BTM
10/10/13PRICE SENSITIVE
CZDAusbiotech Presentation
19/09/13
CZD510(k) Regulatory Submission For NovoSorb Wound Dressing
18/09/13
CZDResponse to ASX Price and Volume Query
11/09/13PRICE SENSITIVE
CZDFull Year Statutory Accounts
28/08/13PRICE SENSITIVE
CZDChange in substantial holding
20/08/13
CZDFinancial Result Guidance
16/08/13PRICE SENSITIVE
CZDAppendix 3B
07/08/13
CZDResponse to Media Speculation
29/07/13PRICE SENSITIVE
CZDTrading halt and request
29/07/13PRICE SENSITIVE
CZDFinal Patient Treated in NovoSorb BTM Clinical Trial
26/07/13PRICE SENSITIVE
CZDChange of Director's Interest Notice
26/07/13
CZDChange of Director's Interest Notice
26/07/13
CZDAppendix 3B
25/07/13
CZDClosing of Share Purchase Plan
23/07/13
CZDNovoSorb Hernia Repair Feasibility Agreement
17/07/13PRICE SENSITIVE
CZDPolyNovo Partners in the Field of Aesthetic Facial Surgery
09/07/13PRICE SENSITIVE
CZDShare Purchase Plan
19/06/13PRICE SENSITIVE
CZDAppendix 3B and Section 708A Notice
14/06/13
CZDShareholder Update
12/06/13
CZDPlacement and Share Purchase Plan
12/06/13PRICE SENSITIVE
CZDTrading Halt
07/06/13PRICE SENSITIVE
CZDInvestor Overview
06/06/13
CZDAmerican Burns Association Presentations
26/04/13
CZDAOD9604 Important Clarifications
26/04/13PRICE SENSITIVE
CZDPositive Results from NovoSorb Human Clinical Trial
17/04/13PRICE SENSITIVE
CZDAppendix 3B
12/04/13
CZDTopical Negative Pressure Human Trial Completed
28/03/13PRICE SENSITIVE
CZDHalf Yearly Report and Accounts
25/02/13PRICE SENSITIVE
CZDUS BARDA Contract Application and BTM Trial Update
18/02/13PRICE SENSITIVE
CZDHalf Year Financial Result Guidance
15/02/13PRICE SENSITIVE
CZDAOD9604 Positive in Osteoarthritis Animal Model
05/02/13PRICE SENSITIVE
CZDPolyNovo Concludes Recruitment for VAC Trial
04/02/13PRICE SENSITIVE
CZDR and D Tax Refund Received
30/01/13PRICE SENSITIVE
CZDChange of Director's Interest Notice
02/01/13
CZDChange in substantial holding
03/12/12
CZDChange of Director's Interest Notice
21/11/12
CZDChange of Director's Interest Notice
21/11/12
CZDChange of Directors Interest Notice
21/11/12
CZDAppendix 3B
21/11/12
CZDFinal Director's Interest Notice
15/11/12
CZDResults of Meeting
14/11/12
refresh Created with Sketch. REFRESH
 

Top Stories

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.